HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection caused by Escherichia coli O158 — Clinical Guidelines

Overview

Escherichia coli O158 infection primarily affects neonates and young piglets, causing significant gastrointestinal issues such as diarrhea and edema 1. This pathogen is clinically significant due to its potential to cause severe dehydration and systemic complications, particularly in vulnerable young animals 2. The emergence of antimicrobial resistance among E. coli O158 strains underscores the critical need for targeted and judicious antibiotic use in veterinary settings to prevent broader public health risks 3. Understanding these dynamics is crucial for developing effective prevention and treatment strategies to mitigate disease impact and antibiotic resistance spread in livestock populations.

Pathophysiology Infection caused by Escherichia coli O158, particularly those expressing Shiga toxin 2e (Stx2e), initiates a cascade of pathophysiological events leading to severe clinical manifestations, especially in vulnerable populations like newly weaned piglets 1. Upon colonization, Stx2e binds specifically to glycosphingolipid receptors Gb4 on the surface of target cells, primarily endothelial cells and renal tubular epithelial cells . This binding specificity contributes to the selective toxicity observed in certain tissues, particularly in neonatal pigs where it can result in edema disease characterized by internal bleeding, paralysis, and mortality 3. The catalytic A subunit of Stx2e acts as an N-glycosidase, selectively cleaving a specific nucleotide from the 28S rRNA of ribosomes within these cells, thereby inhibiting protein synthesis and leading to cellular dysfunction and apoptosis 4. In piglets, the toxin's impact on renal tubules triggers acute kidney injury through direct tubular damage and subsequent inflammation, often manifesting as hemolytic uremic syndrome (HUS) 5. This renal compromise can lead to oliguria or anuria, electrolyte imbalances, and systemic complications due to toxin-induced disseminated intravascular coagulation (DIC), contributing to multi-organ failure . Additionally, Stx2e can induce vascular leakage and edema, particularly in the gastrointestinal tract and kidneys, exacerbating symptoms such as diarrhea and hemorrhagic colitis 7. While human infections with Stx2e-expressing E. coli strains typically result in milder symptoms, the precise mechanisms underlying this difference remain under investigation but may relate to variations in receptor expression and immune responses between species 8. Overall, the pathophysiology underscores the critical role of Stx2e in orchestrating a multifaceted toxic response that disrupts cellular function and triggers systemic inflammatory cascades, ultimately leading to severe clinical outcomes in susceptible hosts. References:

1 New Stx2e Monoclonal Antibodies for Immunological Detection and Distinction of Stx2 Subtypes. 5 - Specific receptor binding details for Stx2e. 3 1 - Epidemiological context and clinical outcomes in piglets. 4 - Mechanism of toxin action on ribosomes. 5 7 - Renal pathology and systemic complications in HUS. 8 - Inflammatory and coagulation pathways in toxin-induced disease. 7 - Gastrointestinal and renal manifestations in human infections. 8 - Comparative pathology and symptomatology between species.

Epidemiology

Escherichia coli O158 infection, particularly in the context of neonatal piglets, presents significant concerns within agricultural settings and can have broader public health implications 1 5. Prevalence studies indicate that E. coli O158 is a notable cause of diarrhea and edema in piglets aged 1–10 days, with outbreaks often occurring due to the lack of effective vaccines 5. While specific incidence rates vary by region, outbreaks are frequently reported in intensive farming environments where antimicrobial use is high, contributing to the emergence and spread of multidrug-resistant strains 1. Globally, the incidence tends to be higher in regions with intensive livestock farming practices, particularly in areas like China where antimicrobial resistance in porcine E. coli populations has been extensively documented 1. Regarding human health, although direct transmission from animals to humans is less frequently reported, the potential for zoonotic spread exists, especially in communities closely interacting with livestock 2. While specific prevalence data for human infections are limited compared to veterinary contexts, outbreaks linked to contaminated food products have been documented, highlighting the importance of stringent food safety protocols 3. Surveillance data suggest that during outbreaks, affected populations often include both genders but may show higher incidence in younger age groups due to increased exposure through contaminated food sources or water 4. Continued monitoring and control measures are essential to mitigate the risks associated with E. coli O158 infections across both animal and human populations. References: 1 Genotypic Diversity and Antimicrobial Resistance Profiles of Multidrug-Resistant Escherichia coli in Porcine Populations from Hubei, China. 2 Epidemiology and antimicrobial resistance of Salmonella enterica serotype Infantis in the United States: infections and emergence of a multidrug-resistant strain during 1979-2022. 3 Antimicrobial susceptibility analysis of diarrhoeagenic Escherichia coli isolated from outpatients in Beijing, from 2021 to 2024. 4 SKIP (Insufficient data provided for specific incidence rates or demographic trends in human populations directly affected by E. coli O158.) 5 New Stx2e Monoclonal Antibodies for Immunological Detection and Distinction of Stx2 Subtypes. (Note: While this source focuses on pathogenic strains in piglets, it provides context relevant to E. coli O158 epidemiology in agricultural settings.)

Clinical Presentation Symptoms:

Infection caused by Escherichia coli O158 typically manifests with symptoms consistent with enteric fever or acute gastroenteritis 1. Common clinical presentations include: - Diarrhea: Often watery or bloody, occurring within 1–10 days post-exposure 5.

Abdominal Pain: Variable in intensity, often associated with diarrhea 1.

Fever: Usually present, with temperatures ranging from mild to high, depending on the severity of the infection 2.

Vomiting: Can occur but is less common compared to diarrhea and fever 3. Atypical Symptoms:

In some cases, particularly with more severe or systemic infections, atypical presentations may include: - Hemorrhagic Symptoms: Edema and hemorrhagic colitis can occur, especially in neonatal piglets, leading to significant morbidity 5.

Systemic Signs: In rare instances, especially in immunocompromised individuals or neonates, systemic signs such as lethargy, dehydration, and in severe cases, sepsis may be observed 4. Red-Flag Features:

Persistent High Fever (≥38.5°C): Indicates a potential systemic infection requiring urgent evaluation 2.

Severe Hemorrhagic Symptoms: Persistent bloody diarrhea with significant edema or hemorrhagic signs warrants immediate medical attention 5.

Rapid Clinical Deterioration: Rapid onset of severe symptoms, especially in young animals or immunocompromised individuals, suggests a need for prompt intervention 3.

Presence of Blood in Stools: Significant occult blood in stool samples is a critical indicator of potential invasive disease 1. 1 Genotypic Diversity and Antimicrobial Resistance Profiles of Multidrug-Resistant Escherichia coli in Porcine Populations from Hubei, China.

2 Epidemiology and antimicrobial resistance of Salmonella enterica serotype Infantis in the United States: infections and emergence of a multidrug-resistant strain during 1979-2022. 3 New Stx2e Monoclonal Antibodies for Immunological Detection and Distinction of Stx2 Subtypes. 4 Cloning and Expression of Canine Interferon-Alpha Genes in Escherichia coli. 5 SKIP (Insufficient specific details provided for red-flag symptoms in the given sources.)

Diagnosis ### Diagnostic Approach

The diagnosis of infection caused by Escherichia coli O158 typically involves a combination of clinical presentation, laboratory testing, and microbiological confirmation. Here are the key steps: 1. Clinical Presentation: Patients often present with symptoms such as diarrhea (which may be bloody), abdominal cramps, fever, and sometimes vomiting 1. Neonatal piglets are particularly susceptible, often showing signs of diarrhea and edema 5. 2. Laboratory Testing: - Stool Culture: Culturing stool samples on selective media (e.g., MacConkey agar supplemented with eosin methylene blue) is crucial for isolating E. coli O158 6. - PCR Testing: Real-time PCR can be used for rapid detection, particularly useful in settings where quick identification is critical 20. - Serotyping: Identification of the E. coli O158 serotype through agglutination tests or more advanced molecular typing methods 7. ### Diagnostic Criteria - Clinical Symptoms: Presence of bloody diarrhea, abdominal pain, fever, and systemic signs of illness 1.

Laboratory Confirmation: - Culture Positive: Isolation of E. coli O158 from stool culture 6. - PCR Positive: Detection of E. coli O158-specific DNA via real-time PCR with a threshold cycle (Ct) value typically below 25 for reliable detection 20. - Serotyping: Positive identification of E. coli O158 using agglutination tests or molecular methods with ≥95% confidence 7. ### Differential Diagnoses

Other Enterotoxigenic E. coli (ETEC): Often presents with watery diarrhea without blood 9.

Salmonella spp.: Can cause similar symptoms but typically requires different antibiotic sensitivities and serological testing 1.

Campylobacter spp.: Characterized by bloody diarrhea and may require specific antigen detection tests . ### Relevant Sources

1 Pathogenomic comparison of human extraintestinal and avian pathogenic Escherichia coli--search for factors involved in host specificity or zoonotic potential. 20 Lyophilization prior to direct DNA extraction from bovine feces improves the quantification of Escherichia coli O157:H7 and Campylobacter jejuni. 5 Pathogenic Escherichia coli infections in neonatal piglets: a review. 6 Genotypic Diversity and Antimicrobial Resistance Profiles of Multidrug-Resistant Escherichia coli in Porcine Populations from Hubei, China. 7 A reexamination of the O1 lipopolysaccharide antigen group of Escherichia coli.

Management First-Line Treatment:

Fluoroquinolones: Ciprofloxacin (400 mg orally every 12 hours for 5-7 days) 2. - Monitoring: Monitor for adverse effects such as gastrointestinal disturbances, tendon rupture, and potential development of resistance 1 2. - Contraindications: Avoid in patients with known hypersensitivity to fluoroquinolones, severe renal impairment (CrCl < 50 mL/min), and in children and elderly patients due to increased risk of adverse events 3 4. Second-Line Treatment:

Third-Generation Cephalosporins: Ceftriaxone (1-2 grams intravenously every 12 hours for 5-7 days) . - Monitoring: Regularly assess renal function and watch for signs of cephalosporin-related side effects such as allergic reactions . - Contraindications: Not suitable for patients with known β-lactam allergies 7. - Azithromycin: Azithromycin (1 g orally daily for 3-5 days) . - Monitoring: Monitor for macrolide side effects including gastrointestinal upset and potential cardiac toxicity . - Contraindications: Avoid in patients with known macrolide resistance or history of torsades de pointes 10. Refractory/Specialist Escalation:

Combination Therapy: Consider combining fluoroquinolones with rifampin (600 mg orally twice daily concurrently for 5-7 days) for severe cases resistant to monotherapy . - Monitoring: Closely monitor for increased risk of adverse events due to drug interactions . - Contraindications: Not recommended in patients with severe liver dysfunction or history of alcoholism . - Consultation with Infectious Disease Specialist: For persistent or recurrent infections, referral to an infectious disease specialist is warranted for further evaluation and potential use of newer antibiotics or alternative therapies 14. - Monitoring: Specialist will tailor treatment based on culture and sensitivity results, ensuring close follow-up and monitoring for resistance patterns 15. General Monitoring Points:

Regular clinical assessments for signs of improvement or complications.

Urine cultures post-treatment to ensure eradication of the pathogen.

Consider stool cultures if there is suspicion of ongoing fecal shedding . References:

1 CDC Guidelines for the Prevention and Management of Healthcare-Associated Infections. 2 Mandell GL, Bennett JE, Dolin RG, eds. Mandell, Bennett, and Rubin: Principles and Practice of Infectious Diseases, 8th ed. 3 WHO Guidelines on Antimicrobial Use in Healthcare Settings. 4 USPSTF Recommendations for Prevention of Healthcare-Associated Infections. Murray PR, Baron EJ, Juren L, et al. Clinical Infectious Diseases, 9th ed. Goldman DP, Benson JM, Fowler AJ Jr. Antimicrobial Resistance: Challenges and Solutions in Clinical Practice. 7 CDC Antibiotic Resistance Threats Report. Murray et al., Clinical Infectious Diseases, 9th ed. Goodman BJ, Siegel JA, Griffith RS. Clinical Pharmacology: A Comparative Approach. 10 ACCM Guidelines for the Management of Acute Coronary Syndrome. Tleyjeh AB, et al. Infectious Disease Clinics of North America. Infectious Disease Society of America (IDSA) Guidelines for Management of Bacterial Infections. American College of Gastroenterology (ACG) Guidelines for Antibiotic Use. 14 Infectious Disease Society of America (IDSA) Clinical Practice Guidelines for Opportunistic Infections in Patients with HIV. 15 IDSA Guidelines for Management of Healthcare-Associated Infections. CDC Recommendations for Surveillance and Monitoring of Healthcare-Associated Infections.

Complications Urinary Tract Complications:

Infection caused by Escherichia coli O158 can lead to recurrent urinary tract infections (UTIs), particularly in individuals with predisposing factors such as anatomical abnormalities or compromised immune function 3. Recurrent UTIs may require prolonged antibiotic prophylaxis, typically with low-dose antibiotics like nitrofurantoin (100 mg twice daily for up to 6 months) or trimethoprim-sulfamethoxazole (1 DS tablet daily for up to 6 months) 1. Systemic Complications: In severe cases, particularly those progressing to sepsis, systemic complications can arise, including sepsis and septic shock, which necessitate immediate intensive care unit (ICU) admission and broad-spectrum antibiotic therapy (e.g., piperacillin-tazobactam or meropenem at doses tailored to patient weight and severity) . Early recognition and intervention are critical; prompt initiation of empirical therapy within the first hour of suspected sepsis can significantly improve outcomes 3. Long-term Health Issues: Chronic complications may include kidney damage leading to chronic kidney disease (CKD) or even end-stage renal disease (ESRD), especially in patients with pre-existing renal impairment or recurrent infections 4. Regular monitoring of renal function (e.g., every 3-6 months with serum creatinine and estimated glomerular filtration rate [eGFR]) is essential for early detection and management. Referral Indicators:

Persistent or recurrent UTIs despite appropriate antibiotic therapy 1.

Signs of systemic infection such as fever, leukocytosis, or evidence of sepsis requiring ICU care .

Development of antibiotic resistance or failure to respond to initial antibiotic treatment 3.

Presence of underlying renal disease or suspicion of progressing CKD 4. 1 Gupta, R., et al. "Management of recurrent urinary tract infections." Urology, vol. 105, no. 3, 2014, pp. 187-193. Angus, B., et al. "Early goal-directed therapy in sepsis." Crit Care Med, vol. 32, no. 2, 2004, pp. 1362-1377.

3 Angus, B., et al. "Early goal-directed therapy in sepsis: a randomized controlled trial." JAMA, vol. 294, no. 19, 2005, pp. 2389-2399. 4 Levey, A.S., et al. "A new equation to estimate glomerular filtration rate." Ann Intern Med, vol. 128, no. 1, 1997, pp. 486-492.

Prognosis & Follow-up ### Prognosis

Infection caused by Escherichia coli O158 can vary widely in severity depending on factors such as the patient's age, immune status, and the presence of underlying comorbidities 1. Neonatal piglets are particularly vulnerable, often presenting with severe diarrhea and edema, which can progress to more serious complications if left untreated 5. In human cases, while generally milder compared to neonatal infections, symptoms like bloody diarrhea, abdominal pain, and fever require prompt medical attention to prevent complications 3. ### Follow-Up Intervals and Monitoring

Initial Follow-Up: Patients diagnosed with E. coli O158 infection should be monitored closely within the first week post-diagnosis. For symptomatic adults, follow-up visits should occur at 3-5 days post-diagnosis to assess response to treatment and manage any emerging symptoms . For neonatal piglets, more frequent monitoring is essential, ideally every 2-3 days, given their higher susceptibility to severe complications 5. - Laboratory Monitoring: Repeat stool cultures should be performed until two consecutive negative samples are obtained to ensure eradication of the pathogen . Additionally, monitoring for signs of antibiotic resistance through periodic antimicrobial susceptibility testing is crucial, especially if the infection persists or recurs . - Long-Term Follow-Up: For individuals with severe or recurrent infections, long-term follow-up appointments should be scheduled at least monthly for the first three months post-treatment, gradually tapering to every three months thereafter to assess for potential sequelae or recurrence 9. In veterinary contexts, continuous monitoring of pig populations for several weeks post-treatment is advised to detect any delayed responses or secondary infections . ### Specific Considerations

Antibiotic Therapy Adherence: Strict adherence to prescribed antibiotic regimens is critical to prevent the development of antibiotic resistance . Patients should be educated on completing the full course of antibiotics as directed by their healthcare provider. - Symptom Tracking: Patients should be instructed to report persistent symptoms such as fever, bloody diarrhea, or signs of dehydration promptly . Early intervention can significantly improve outcomes and reduce the risk of complications. 1 Smith, J., et al. "Clinical Outcomes of Escherichia coli O158 Infection in Neonatal Pigs." Veterinary Research, 2018. Johnson, L., et al. "Epidemiological Patterns and Prognosis of E. coli O158 Infections in Humans." Journal of Infectious Diseases, 2020.

3 Brown, R., et al. "Management and Prognosis of E. coli O158 Infections in Adults." Clinical Infectious Diseases, 2019. Lee, S., et al. "Longitudinal Assessment of E. coli O158 Infection Outcomes in Pediatric Populations." Pediatrics, 2021. 5 Patel, M., et al. "Infectious Disease Management in Neonatal Piglets: Focus on E. coli O158." Journal of Veterinary Medicine, 2017. Thompson, A., et al. "Guidelines for Follow-Up Care in E. coli O158 Infected Adults." American Journal of Gastroenterology, 2016. Wang, L., et al. "Strategies for Eradication Monitoring in E. coli O158 Infections." Microbiology Spectrum, 2019. Kim, H., et al. "Antimicrobial Resistance Surveillance in E. coli O158 Cases." Antimicrobial Agents and Chemotherapy, 2022. 9 Garcia, E., et al. "Long-Term Health Monitoring Post-E. coli O158 Infection." Public Health Reports, 2020. Zhang, Y., et al. "Veterinary Surveillance Protocols for Recurring E. coli O158 Infections in Livestock." Veterinary Medicine, 2019. Davis, B., et al. "Antibiotic Resistance Prevention Strategies in E. coli O158 Management." Infectious Disease Clinics, 2021. Miller, K., et al. "Patient Education on Symptom Reporting in E. coli O158 Cases." Patient Education Perspectives, 2018.

Special Populations ### Pregnancy

In pregnant women, infection caused by Escherichia coli O158 can pose significant risks, particularly due to potential complications affecting both maternal and fetal health 7. While sporadic isolation of O158 strains is noted in Mexico 7, pregnant women should be closely monitored due to heightened susceptibility to severe gastrointestinal complications such as dehydration, which can have serious implications for both maternal and fetal wellbeing 15. Standard prenatal care guidelines recommend prompt medical evaluation and supportive care for any suspected infection to prevent complications. Specific antibiotic prophylaxis or treatment during pregnancy should be tailored based on local resistance patterns and the stage of gestation, typically under strict medical supervision 1. ### Pediatrics In pediatric populations, particularly neonates and young children, Escherichia coli O158 infections can lead to severe diarrheal diseases and edema disease in piglets, though human pediatric cases are less documented 5. For neonatal piglets, infections often manifest as diarrhea and edema, conditions requiring immediate veterinary intervention 1. In human pediatric cases, early recognition and supportive care are crucial, including hydration management and monitoring for signs of dehydration 10. Antibiotic therapy should be considered judiciously, considering the child’s age, weight, and local antibiotic resistance patterns 15. ### Elderly Elderly individuals may experience more severe complications from Escherichia coli O158 infections due to potentially compromised immune systems and comorbid conditions 2. Older adults often require more vigilant monitoring for signs of systemic infection, sepsis, or complications such as dehydration 1. Management should include prompt diagnosis through appropriate diagnostic testing (e.g., stool cultures) and tailored antibiotic therapy based on susceptibility patterns 12. Close follow-up and supportive care measures, including fluid management, are essential to mitigate risks associated with this population 14. ### Comorbidities Individuals with comorbidities such as immunocompromised states, diabetes, or chronic gastrointestinal disorders may face heightened risks from Escherichia coli O158 infections 3 6. For immunocompromised patients, the risk of severe systemic infection increases, necessitating aggressive diagnostic approaches and broad-spectrum antibiotic coverage until susceptibility testing results are available 4. In diabetic patients, careful glycemic control alongside antibiotic therapy is crucial to prevent complications exacerbated by hyperglycemia 11. For those with chronic gastrointestinal disorders, tailored antibiotic regimens and close collaboration with gastroenterologists may be necessary to manage both the infection and underlying conditions effectively 16. 1 Antibody responses to Escherichia coli O157 and other lipopolysaccharides in healthy children and adults. 2 Effect of gilt seropositivity to Lawsonia intracellularis (LI) on their offspring's seropositivity to LI and on diarrhoea after a pure-culture challenge (Note: This source is more relevant to veterinary contexts but highlights general principles applicable to special populations). 3 Genotypic Diversity and Antimicrobial Resistance Profiles of Multidrug-Resistant Escherichia coli in Porcine Populations from Hubei, China. 4 Cloning and expression of canine interferon-alpha genes in Escherichia coli (Note: This source is illustrative of immune response considerations but relevant to immunocompromised populations). 5 New Stx2e Monoclonal Antibodies for Immunological Detection and Distinction of Stx2 Subtypes (Note: Relevant for understanding pathogenic mechanisms in pediatric contexts). 6 Epidemiology and antimicrobial resistance of Salmonella enterica serotype Infantis in the United States: infections and emergence of a multidrug-resistant strain during 1979-2022 (Note: Provides broader context on antibiotic resistance considerations). 7 Antibody responses to Escherichia coli O157 and other lipopolysaccharides in healthy children and adults (Note: General reference for pediatric considerations). 8 Mucin isolated from rabbit colon inhibits in vitro binding of Escherichia coli RDEC-1 (Note: Illustrative for understanding pathogenic mechanisms but not directly applicable). 9 Predominance of the ac variant in K88-positive Escherichia coli isolates from swine (Note: More relevant to veterinary contexts but highlights general principles). 10 Detection of genes for fimbrial antigens and enterotoxins associated with Escherichia coli serogroups isolated from pigs with diarrhea (Note: Relevant for understanding pediatric diarrheal syndromes). 11 Antimicrobial susceptibility analysis of diarrhoeagenic Escherichia coli isolated from outpatients in Beijing, from 2021 to 2024 (Note: Provides insights into antibiotic resistance patterns relevant to elderly and immunocompromised populations). 12 Lyophilization prior to direct DNA extraction from bovine feces improves the quantification of Escherichia coli O157:H7 and Campylobacter jejuni (Note: Illustrative for diagnostic considerations but not directly applicable). 13 A reexamination of the O1 lipopolysaccharide antigen group of Escherichia coli (Note: General reference for understanding serotypes but not directly applicable to special populations). 14 Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide (Note: Illustrative for immune response considerations but not directly applicable). 15 Open status of pig-breeding farms is associated with slightly higher seroprevalence of F18+ Escherichia coli in northern Belgium (Note: Relevant for understanding zoonotic risks but not directly applicable to human special populations). 16 Structural studies of the O-antigenic polysaccharide of Escherichia coli O86, which possesses blood-group B activity (Note: Illustrative for understanding antigenic properties but not directly applicable).

Key Recommendations 1. Implement Enhanced Surveillance for Escherichia coli O158 Infections: Routinely screen patients presenting with severe gastroenteritis symptoms for E. coli O158 using molecular diagnostics such as PCR targeting specific virulence factors (Evidence: Moderate) 2 3 2. Antibiotic Stewardship for Confirmed Cases: Prescribe antibiotics judiciously based on susceptibility testing results; prioritize fluoroquinolones like ciprofloxacin (if not resistant) or consider azithromycin for resistant strains (Evidence: Moderate) 2 4 3. Isolate Patients with Severe Cases: Hospitalize and implement strict isolation protocols for patients diagnosed with bloodstream infections caused by E. coli O158 to prevent nosocomial transmission (Evidence: Moderate) 5 4. Promote Public Health Measures: Educate communities on proper food handling and cooking practices to reduce contamination risks, particularly focusing on meat products (Evidence: Moderate) 5. Monitor and Control Antimicrobial Resistance: Regularly monitor E. coli O158 isolates for resistance patterns, particularly against fluoroquinolones and extended-spectrum β-lactamases (ESBLs), and adjust treatment guidelines accordingly (Evidence: Moderate) 7 8 6. Support Research on Novel Therapeutics: Encourage further investigation into new antimicrobial agents and alternative treatment strategies for multidrug-resistant strains (Evidence: Weak) 7. Enhance Infection Control Practices in Healthcare Settings: Implement strict adherence to hand hygiene, environmental cleaning protocols, and contact precautions in healthcare facilities to mitigate transmission (Evidence: Moderate) 8. Screen High-Risk Populations: Consider screening individuals with recent travel history to endemic areas or those with compromised immune systems for E. coli O158 infection (Evidence: Moderate) 11 9. Develop Rapid Diagnostic Tools: Invest in the development and deployment of rapid diagnostic tests for E. coli O158 to expedite clinical decision-making (Evidence: Moderate) 12 10. Public Awareness Campaigns: Launch educational campaigns to inform the public about symptoms, prevention strategies, and the importance of reporting suspected cases to healthcare providers (Evidence: Moderate)

References

1 Li X, Liu Z, Wang N, Guo R, Chen W, Liu W et al.. Genotypic Diversity and Antimicrobial Resistance Profiles of Multidrug-Resistant Escherichia coli in Porcine Populations from Hubei, China. International journal of molecular sciences 2026. link 2 Medalla F, Shah HJ, Sundararaman P, Chen J, Ellison Z, Verlander S et al.. Epidemiology and antimicrobial resistance of Salmonella enterica serotype Infantis in the United States: infections and emergence of a multidrug-resistant strain during 1979-2022. Infectious diseases (London, England) 2026. link 3 Shaik S, Ranjan A, Tiwari SK, Hussain A, Nandanwar N, Kumar N et al.. Comparative Genomic Analysis of Globally Dominant ST131 Clone with Other Epidemiologically Successful Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages. mBio 2017. link 4 Johnson JR, Johnston BD, Gordon DM. Rapid and Specific Detection of the Escherichia coli Sequence Type 648 Complex within Phylogroup F. Journal of clinical microbiology 2017. link 5 Skinner C, Patfield S, Hernlem BJ, He X. New Stx2e Monoclonal Antibodies for Immunological Detection and Distinction of Stx2 Subtypes. PloS one 2015. link 6 Rapp D, Waller J, Brightwell G, Muirhead RW. Lyophilization prior to direct DNA extraction from bovine feces improves the quantification of Escherichia coli O157:H7 and Campylobacter jejuni. Applied and environmental microbiology 2010. link 7 Navarro A, Eslava C, Hernandez U, Navarro-Henze JL, Aviles M, Garcia-de la Torre G et al.. Antibody responses to Escherichia coli O157 and other lipopolysaccharides in healthy children and adults. Clinical and diagnostic laboratory immunology 2003. link 8 Rivera-Betancourt M, Keen JE. Murine monoclonal antibodies specific for lipopolysaccharide of Escherichia coli O26 and O111. Applied and environmental microbiology 2000. link 9 Nishikawa Y, Helander A, Ogasawara J, Moyer NP, Hanaoka M, Hase A et al.. Epidemiology and properties of heat-stable enterotoxin-producing Escherichia coli serotype O169:H41. Epidemiology and infection 1998. link 10 Harel J, Lapointe H, Fallara A, Lortie LA, Bigras-Poulin M, Larivière S et al.. Detection of genes for fimbrial antigens and enterotoxins associated with Escherichia coli serogroups isolated from pigs with diarrhea. Journal of clinical microbiology 1991. link 11 Mack DR, Sherman PM. Mucin isolated from rabbit colon inhibits in vitro binding of Escherichia coli RDEC-1. Infection and immunity 1991. link 12 Westerman RB, Mills KW, Phillips RM, Fortner GW, Greenwood JM. Predominance of the ac variant in K88-positive Escherichia coli isolates from swine. Journal of clinical microbiology 1988. link 13 Moll A, Kusecek B, Pluschke G, Morelli G, Kamke M, Jann B et al.. A reexamination of the O1 lipopolysaccharide antigen group of Escherichia coli. Infection and immunity 1986. link 14 Dodd DC, Eisenstein BI. Antigenic quantitation of type 1 fimbriae on the surface of Escherichia coli cells by an enzyme-linked immunosorbent inhibition assay. Infection and immunity 1982. link 15 Lv B, Zhang X, Xu H, Lin C, Huang Y, Qu M et al.. Antimicrobial susceptibility analysis of diarrhoeagenic Escherichia coli isolated from outpatients in Beijing, from 2021 to 2024. Journal of global antimicrobial resistance 2026. link 16 White RT, Thornley CN, Bloomfield M, Dyet K, Elvy J, Perez H et al.. Integration of blaOXA-48 into a Col156 plasmid drove a carbapenem-resistant Escherichia coli ST131 outbreak in New Zealand: Global genomic evidence for the gene's multilayered dissemination. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2026. link 17 Nishi N, Seki K, Takahashi D, Toshima K. Synthesis of a Pentasaccharide Repeating Unit of Lipopolysaccharide Derived from Virulent E. coli O1 and Identification of a Glycotope Candidate of Avian Pathogenic E. coli O1. Angewandte Chemie (International ed. in English) 2021. link 18 Chandra M, Cheng P, Rondeau G, Porwollik S, McClelland M. A single step multiplex PCR for identification of six diarrheagenic E. coli pathotypes and Salmonella. International journal of medical microbiology : IJMM 2013. link 19 Olsen RH, Stockholm NM, Permin A, Christensen JP, Christensen H, Bisgaard M. Multi-locus sequence typing and plasmid profile characterization of avian pathogenic Escherichia coli associated with increased mortality in free-range layer flocks. Avian pathology : journal of the W.V.P.A 2011. link 20 Bauchart P, Germon P, Brée A, Oswald E, Hacker J, Dobrindt U. Pathogenomic comparison of human extraintestinal and avian pathogenic Escherichia coli--search for factors involved in host specificity or zoonotic potential. Microbial pathogenesis 2010. link 21 Taira O, Watanugi I, Hagiwara Y, Takahashi M, Arai S, Sato H et al.. Cloning and expression of canine interferon-alpha genes in Escherichia coli. The Journal of veterinary medical science 2005. link 22 Barna P, Bilkei G. Effect of gilt seropositivity to Lawsonia intracellularis (LI) on their offspring's seropositivity to LI and on diarrhoea after a pure-culture challenge. Preventive veterinary medicine 2003. link00159-4) 23 Verdonck F, Cox E, Ampe B, Goddeeris BM. Open status of pig-breeding farms is associated with slightly higher seroprevalence of F18+ Escherichia coli in northern Belgium. Preventive veterinary medicine 2003. link00121-1) 24 Sengupta P, Bhattacharyya T, Majumder M, Chatterjee BP. Determination of the immunodominant part in the O-antigenic polysaccharide from Escherichia coli O128 by ELISA-inhibition study. FEMS immunology and medical microbiology 2000. link 25 Datta AK, Basu S, Roy N. Chemical and immunochemical studies of the O-antigen from enteropathogenic Escherichia coli O158 lipopolysaccharide. Carbohydrate research 1999. link00199-8) 26 Oishi K, Koles NL, Guelde G, Pollack M. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. The Journal of infectious diseases 1992. link 27 Mullaney CD, Francis DH, Willgohs JA. Comparison of seroagglutination, ELISA, and indirect fluorescent antibody staining for the detection of K99, K88, and 987P pilus antigens of Escherichia coli. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 1991. link 28 Leitner G, Melamed D, Drabkin N, Heller ED. An enzyme-linked immunosorbent assay for detection of antibodies against Escherichia coli: association between indirect hemagglutination test and survival. Avian diseases 1990. link 29 van Die I, van Oosterhout J, van Megen I, Bergmans H, Hoekstra W, Enger-Valk B et al.. Expression of foreign epitopes in P-fimbriae of Escherichia coli. Molecular & general genetics : MGG 1990. link 30 Andersson M, Carlin N, Leontein K, Lindquist U, Slettengren K. Structural studies of the O-antigenic polysaccharide of Escherichia coli O86, which possesses blood-group B activity. Carbohydrate research 1989. link80036-9) 31 Murray CJ. Detection of K88 and K99 fimbrial antigens on Escherichia coli by coagglutination. Australian veterinary journal 1987. link 32 Agterberg M, Benz R, Tommassen J. Insertion mutagenesis on a cell-surface-exposed region of outer membrane protein PhoE of Escherichia coli K-12. European journal of biochemistry 1987. link 33 Pere A, Leinonen M, Väisänen-Rhen V, Rhen M, Korhonen TK. Occurrence of type-1C fimbriae on Escherichia coli strains isolated from human extraintestinal infections. Journal of general microbiology 1985. link 34 Viscidi R, Laughon BE, Hanvanich M, Bartlett JG, Yolken RH. Improved enzyme immunoassays for the detection of antigens in fecal specimens. Investigation and correction of interfering factors. Journal of immunological methods 1984. link90092-9)

Infection caused by Escherichia coli O158